Managing Immune-Related Adverse Events in Trials
Managing Immune-Related Adverse Events in Trials Effective Management of Immune-Related Adverse Events in Oncology Trials Introduction to Immune-Related Adverse Events Immune-related adverse events (irAEs) are a hallmark safety concern in oncology trials involving immunotherapies, particularly immune checkpoint inhibitors (ICIs) and CAR-T cell therapies. Unlike toxicities from chemotherapy, irAEs arise from immune system hyperactivation, leading to…
Read More “Managing Immune-Related Adverse Events in Trials” »